New chiral methyloxyiminomethyl(MOIM) beta-adrenergic antagonists. (S)- and (R)-N-[3-(alkylamino)-2-hydroxypropylidene](p-chlorophenylmethyloxy)amines as probes for determining enantiomeric specificity in the class of MOIM-type beta-adrenergic blocking agents